Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX-100 vs Placebo for Acute Suicidal Ideation in Bipolar Depression
NCT03396601Phase 3Active, not recruiting
- Sponsor
- NRx Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of NRX-100 in bipolar disorder (BD), suicidal ideation, sponsored by NRx Pharmaceuticals. Started Jun 2019; status: active, not recruiting.
02
Drugs
NRX-100
03
Conditions
bipolar disorder (BD)suicidal ideation
Beyond the preview
Go deeper on NCT03396601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396601.